Ten-year survival, trends and risk stratification of newly diagnosed idiopathic pulmonary arterial hypertension in China: insights from a national multicenter prospective registry

Data on the 10-year survival of incident IPAH in China is lacking. The changing trend of characteristics and survival of IPAH over the past decade has yet been demonstrated. The 4-stratum risk model needs further validation in different cohorts. Incident cases of IPAH identified in the national multicenter prospective registry of PAH from 2009 to 2019 were analyzed. Patients with at least two of the three acquired variables (WHO-FC, 6MWD, NT-pro BNP/BNP) were included for risk stratification. 605 incident patients with IPAH were included (age: 35 ± 12 years; 75.2% females). The 1-, 3-, 5-, and 10-year survival of the whole cohort was 95.4%, 84.3%, 72.3%, and 53.4%, respectively. Aside from traditional prognostic factors of PAH, TG/HDL-c ratio > 1.4 was independently associated with 10-year mortality (HR 1.458). Compared with 2009–2014, patients enrolled in 2015–2019 showed shorter diagnostic delays and less severe diseases at baseline. The 1-year and 3-year survival improved over time, with increased prescription of targeted therapy and initial combination therapy. With the 4-stratum risk model, patients classified into different risk groups showed significantly different survival at both baseline (C-statistic 0.66) and follow-up (C-statistic 0.83) when three variables were available. The 10-year survival of IPAH patients in China has shown improvement, though further gains are needed. TG/HDL-c > 1.4 was associated with increased10-year mortality. Over the past decade, advances in the management of IPAH have contributed to better survival. The 4-stratum model demonstrated a good performance in Chinese patients with IPAH when three variables were available. No. NCT01417338 (Registration Date 200908).

• Publication year

  2025

• Venue

  BMC Pulmonary Medicine

• Publication date

  2025-11-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s12890-025-04025-wPMID 41299390PMCID 12659585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

  2024cited by this paper
• The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance

  2024cited by this paper
• Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study

  2024cited by this paper
• Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting?

  2023cited by this paper
• Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database

  2023cited by this paper
• Characteristics, goal‐oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry

  2022cited by this paper
• Characteristics, long-term survival and risk assessment of pediatric pulmonary arterial hypertension in China: Insights from a national multicenter prospective registry.

  2022cited by this paper
• 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

  2022influential reference
• A Retrospective Population-Based Survival Study of Idiopathic Pulmonary Arterial Hypertension in Korea

  2022cited by this paper
• Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry

  2021influential reference
• External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry

  2021cited by this paper
• COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

  2021cited by this paper
• High TG/HDL ratio suggests a higher risk of metabolic syndrome among an elderly Chinese population: a cross-sectional study

  2021influential reference
• Pulmonary hypertension in chronic lung disease and hypoxia

  2019cited by this paper
• Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Systemic Inflammation in Patients with Idiopathic Pulmonary Arterial Hypertension

  2019cited by this paper
• Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan.

  2019cited by this paper
• Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension

  2018cited by this paper
• Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension

  2018cited by this paper
• Pulmonary arterial hypertension in a multi‐ethnic Asian population: Characteristics, survival and mortality predictors from a 14‐year follow‐up study

  2018cited by this paper
• The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.

  2017influential reference
• A systematic review of genetic mutations in pulmonary arterial hypertension

  2017cited by this paper
• Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension.

  2017cited by this paper
• 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

  2016cited by this paper
• 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

  2016cited by this paper
• Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension

  2015cited by this paper
• Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan.

  2014cited by this paper
• Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.

  2013cited by this paper
• An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

  2012cited by this paper
• Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

  2012cited by this paper
• Survival in pulmonary hypertension in Spain: insights from the Spanish registry

  2012cited by this paper
• Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era.

  2011influential reference
• Predicting survival in pulmonary arterial hypertension: time to combine markers.

  2011cited by this paper
• ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre

  2011cited by this paper
• Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

  2010cited by this paper
• Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

  2010cited by this paper
• Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

  2009cited by this paper
• Insulin resistance in pulmonary arterial hypertension

  2008influential reference
• Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension.

  2007influential reference
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• No citing papers are available for this paper.